Expanded Access Program for Inotersen (ISIS 420915) in Patients With Hereditary Transthyretin Amyloidosis (hATTR)
Phase of Trial: Clinical Phase Unknown
Latest Information Update: 21 Nov 2018
At a glance
- Drugs Inotersen (Primary)
- Indications Amyloid polyneuropathy
- Focus Expanded access; Therapeutic Use
- Sponsors Ionis Pharmaceuticals
- 08 Nov 2018 Status changed from recruiting to completed.
- 08 Jan 2018 Status changed from planning to recruiting.
- 08 Nov 2017 New trial record